FEMY
Femasys Inc.0.8537
-0.0136-1.57%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
49.92MP/E (TTM)
-Basic EPS (TTM)
-0.69Dividend Yield
0%Recent Filings
8-K
FDA nod, $12M financing
Femasys secured FDA IDE approval on November 3, 2025, to advance the final phase (Part B) of the FINALE pivotal trial for non-surgical FemBloc permanent birth control. It raised $12 million via senior secured convertible notes at 8.5% interest, maturing in 10 years, with warrants potentially adding $46 million if exercised. Funds refinance debt and push commercialization. Warrants may never exercise.
8-K
Nasdaq equity compliance claim
Femasys faces Nasdaq scrutiny after its common stock's market value stayed below $35 million for 30 days, breaching listing rule 5550(b)(2). Yet it claims pro forma stockholders' equity hit $5.2 million as of October 15, 2025, post-$8.0 million offering and warrant exercises, satisfying the $2.5 million minimum. Nasdaq monitors compliance; delisting looms if next report fails. Equity edges up.
8-K
COO Currie retires December 15
Femasys COO Daniel Currie announced retirement on October 13, 2025, effective December 15 after 20+ years, citing health and family. Separation agreement grants vesting of 315,778 stock options and COBRA benefits through 2026, with non-compete covenants intact. Currie stays through transition. Smooth handover aids continuity.
8-K
Femasys prices $8M offering
Femasys launched an underwritten public offering on August 25, 2025, pricing 10.4M common shares and pre-funded warrants for 11.8M shares alongside common warrants for 22.2M shares at $0.36 each, expecting $8.0M gross proceeds before expenses. Closing is slated for August 27, subject to conditions. Funds will fuel commercial expansion and product development. Warrants expire in five years.
8-K
UK approval for FemBloc
Femasys secured MHRA approval for FemBloc permanent birth control on August 20, 2025, following its CE mark. This clears the path for UK commercialization via strategic partners in the NHS-dominated market. Regulatory wins build momentum. Forward-looking commercialization plans carry execution risks.
IPO
Website
Employees
Sector
Industry
EMBC
Embecta Corp.
11.89-0.04
EVFM
Evofem Biosciences, Inc.
0.01-0.00
HAE
Haemonetics Corporation
81.11+0.71
HOLX
Hologic, Inc.
75.02-0.17
IVF
INVO Fertility, Inc.
1.18-0.01
OMI
Owens & Minor, Inc.
3.10+0.09
PLSE
Pulse Biosciences, Inc
14.23+0.10
SERA
Sera Prognostics, Inc.
3.56+0.18
TMCI
Treace Medical Concepts, Inc.
2.70-0.07
UTMD
Utah Medical Products, Inc.
58.43+0.94